Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-01-31
2006-01-31
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S298000
Reexamination Certificate
active
06992094
ABSTRACT:
The invention concerns novel diarylselenide compounds corresponding to the general formula (I) and the use thereof in pharmaceutical compositions in human or veterinary medicine (in the treatment of dermatological, rheumatic, cardiovascular and ophthalmologic pathologies in particular), or in cosmetic compositions.
REFERENCES:
patent: 0 170 105 (1986-02-01), None
patent: 0 661 258 (1995-07-01), None
patent: 0 679 630 (1995-11-01), None
patent: 67-9630 (1995-11-01), None
patent: WO 92 20643 (1992-11-01), None
patent: WO 93 21146 (1993-10-01), None
patent: WO 94 12880 (1994-06-01), None
patent: 97-16422 (1997-05-01), None
patent: WO 97 16422 (1997-05-01), None
patent: 98 22423 (1998-05-01), None
Nakanishi et. al., Inverse Substituent Effect on 77 Se NMR chemical shifts in naphthalene systems with linear 4 C-6e Se4 bond: 1[8-(p-YC6H4Se)ClOH6]SeSe[ClOH6(SeC4y-p)-8′]-1, vs. 1-(MeSe)-8-(p-YC6H4Se)CloH6, Chem. Lett. vol. 11, pp. 947-948, vol. 11.
Oncology, vol. 15, No. 11, Nov. 2001.
Nakanishi, et. al., “Structure of 1-(Arylselanyl)naphthalenes-Y Dependence in 1-(p-YC6H4Se)C10H7”, Eur. J. Org. Chem., 2001, 3933-3943.
Diaz, “Solution-Phase Synthesis of Diaryl Selenides Using Polymer-Supported Borohydride”, Organic Letters, vol. 2, No. 12, pp. 1705-1708, Year 2000.
Ca 85: 192503, “Some reactions of 1-lithio-2-n-butyl-1,2-dihydropyrine. VI. Synthesis of Beta-substituted pyridines”, Knaus et. al.
Lendaris et al. “Reach through claims . . . ” Intellectual property update v. 4, No. 15, (2004).
Madhaven N. “Amended final report . . . ” CA 134:315849 (2000).
“Retinobenzoic Acids, Structure-Activity Relationships of Aromatic Amides with Retinoidal Activity”, J. Med. Chem. 1988, vol. 31, pp. 2182-2192.
“Structural Modifications of 6-Naphthalene-2-Carboxylate Retinoids”, Kuo-Long Yu, et al, Bioorganic & Medicinal Chemistry Letters, vol. 6, No. 23, pp. 2865-2870.
“The Retinoid Receptors”, Susan M. Pemrick et al, Leukemia, vol. 8, Suppl. 3, 1994, pp. S1-S10.
Eremia, S. et al., “Prevention of Temporal Alopecia Following Rhytidectomy; the Prophylactic Use on Minoxidil. A Study of 60 Patients”, Dematol Surg Jan. 2002;28(1):66-74.
Christodoulou, C. et al., “Effectiveness of the MSC Cold Cap System in the Prevention of Chemotherapy-Induced Alopecia”, Oncology 2002;62(2):97-102.
Chen, C.H. et al., “Targeting Expression of the Human Vitamin D Receptors to the Keratinocytes of Vitamin D Receptor Null Mice Prevents Alopecia”, Endocrinology Dec. 2001; 142(12):5386-9.
Jahnukainen K. et al., “Amifostine Protects Against Early but not Late Toxic Effects of Doxorubicin in Infant Rats”, Cancer Res Sep. 1, 2001;61(17):6423-7.
Davis, S.T. et al, “Prevention of Chemotherapy-Induced Alopecia in Rats by CDK Inhibitors”, Science Jan. 5, 2001; 291(5501):134-7.
Katsimbri, P. et al., “Prevention of Chemotherapy-Induced Alopecia Using an Effective Scalp Cooling System”, Eur J Cancer Apr. 2000; 36(6):766-71.
Hidalgo M. et al., “A Phase I Trial of Topical Topitriol (calcitriol, 1,25-dihydroxyvitamin D3) to Prevent Chemotherapy-Induced Alopecia” Anticancer Drugs Apr. 1990; 10(4):393-5.
Chen, G. et al., “Protection Against Cyclophosphamide-Induced Alopecia and Inhibition of Mammary Tumor Growth by Topical 1,25-dihydroxyvitamin D3 in Mice”, Int J Cancer Jan. 19, 1998; 75(2):303-9.
Ron, I.G. et al., Scalp Cooling in the Prevention of Alopecia in Patients Receiving Depilating Chemotherapy, Support Care Cancer Mar. 1997;5(2):136-8.
Lemenager, M. et al., “Effectiveness of Cold Cap in the Prevention of Doxetaxel-Induced Alopecia”, Eur J Cancer Feb. 1997;33(2):297-300.
Srendi, B. et al., “Bone Marrow-Sparing and Prevention of Alopecia by AS101 in Non-Small-Cell Lung Cancer Patients Treated with Carboplatin and Etoposide”, J Clin Oncol Sep. 1995;13(9):2342-53.
Jimenez, J.J., “Pretreatment with 1,25(OH)2D3 Protects from Cytoxan-Induced Alopecia without Protecting the Leukemic Cells from Cytoxan”, Am J Med Sci Aug. 1995;310(2):43-7.
Hussein, A.M., “Protection Against Cytosine Arabinoside-Induced Alopecia by Minoxidil in a Rat Animal Model”, Int J Dermato Jul. 1995;34(7):470-3.
Hussein, A.M. et al., “Protection Against Chemotherapy-Induced Alopecia by Cyclosporin A in the Newborn Rat Animal Model”, Dematology 1995;190(3):192-6.
Rodriguez, R. et al., “Minoxidil (Mx) as a Prophylaxis of Doxorubicin-Induced Alopecia”, Ann Oncol Oct. 1994;5(8):769-70.
Balsari, A.L. et al., “Protection Against Doxorubicin-Induced Alopecia in Rats by Liposome-Entrapped Monoclonal Antibodies”, FASEB J Feb. 1994;8(2):226-30.
Tollenaar, R.A. et al., “Scalp Cooling Has No Place in the Prevention of Alopecia in Adjuvant Chemotherapy for Breast Cancer”, Eur J Cancer 1994;30A(10):1448-53.
Lemenager, M. et al., “Docetaxel-Induced Alopecia Can be Prevented”, The Lancet: Letters to the Editor, vol. 346, Aug. 5, 1995, pp. 371-372.
Ramos-e-Silva, M., “Male Pattern Hair Loss: Prevention Rather Than Regrowth”, Int J of Dermatology 2000, 39, 728-731.
Fisher, D.A. Deideratum Dermatologica -Wanted: A Dependable and Safe Means to Prevent Alopecia Areata Progression . . . , Int J of Dermatology 1996, 37, 497-499.
Takahata, K. et al., “Protection from Chemotherapy-Induced Alopecia by Docosahexaenoic Acid”, Lipids, vol. 34, S105. (1999).
Jimenez, J.J. et al., “Vitamin D3and Chemotherapy-Induced Alopecia”, Nutrition 12:448-453, 1996.
M.F. Boehm et al; Journal of Medicinal Chemistry, vol. 38, 1995, pp. 3146-3155, XP002115271.
Bernardon Jean-Michael
Diaz Philippe
Buchanan Ingersoll P.C.
Chang Celia
Galderma Research & Development S.N.C.
LandOfFree
Diarylselenide compounds and their use in human or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diarylselenide compounds and their use in human or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diarylselenide compounds and their use in human or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3589825